trophon®2
Masterful Microbial Defense

trophon® goes further to deliver the broadest* patient protection.

An extensive list of pathogens have been implicated in healthcare-associated infections (HAIs). High level disinfection (HLD) of semi-critical medical devices such as ultrasound probes is an essential part of the fight against HAIs.

Nanosonics has conducted extensive laboratory testing to validate the effectiveness of trophon and its sonicated disinfectant mist technology

As a result, trophon is the only automated HLD technology for transvaginal, transrectal surface ultrasound probes to meet mandatory microbial efficacy test requirements for both CE mark and FDA registration.

This includes testing that meets the required EN, ASTM and AOAC standards to demonstrate:1-3

  • Bactericidal efficacy
  • Virucidal efficacy (enveloped and non-enveloped viruses)
  • Fungicidal efficacy
  • Mycobactericidal efficacy

Going Beyond the Mandatory Requirements

In addition to mandatory testing, trophon is demonstrated to eliminate an extended range of clinically relevant pathogens including:

  • Multi-drug resistant bacteria, such as MRSA and VRE
  • Blood borne viruses sexually transmitted pathogens, such as chlamydia, gonorrhea, herpes, HIV, hepatitis A, B and C as well as HPV
  • Clostridium difficile spores
Vegetative bacteria Fungi
Staphylococcus aureus Trichophyton mentagrophytes
Pseudomonas aeruginosa
Viruses
Salmonella choleraesuis
Polio virus type 1
Methicillin-resistant Staphylococcus aureus
Herpes simplex virus type 1 
Vancomycin-resistant Enterococcus faecalis Hepatitis A virus
Carbapenam-resistant Escherichia coli Adenovirus type 2
Neisseria gonorrhoea Human hepatitis B virus surrogate (duck hepatitis B virus) 
Chlamydia trachomatis (serotype K) Human immunodeficiency virus type 1ϯ
Mycobacteria Human norovirus surrogate
Mycobacterium terrae Human rotavirus
Bacterial endospores Human papillomavirus (HPV16 and HPV18)
Clostridium difficileϯ Hepatitis C virus surrogate (Bovine viral diarrhea virus)
Clostridium sporogenesϯϯ  
Bacillus subtilisϯϯ  

ϯ trophon has been shown to inactivate these pathogens in laboratory tests.

ϯϯ Effective at extended contact time per FDA requirements for HLDs.

trophon Performance Demonstrated in Clinical Settings

trophon outperforms other methods of disinfection that have been tested in similar clinical settings:4,5

  • Low level disinfection (LLD) wipes fail to systematically remove bacterial contamination from patient-used ultrasound probes.4
  • 80% of probe handles are contaminated with bacteria after soaking in glutaraldehyde when the handle is not immersed, per typical practice.5
“We chose the trophon system because it stood out from the rest. We like the efficacy of the product and the fact it’s proven to kill high-risk, cancer-causing HPV”
Lisa Antsy
Manager of Medical Reprocessing
Grand River Hospital in Ontario, Canada

* Broadest efficacy spectrum as compared to ultrasound probe disinfection with UVC and ClO2 wipes systems.

The trophon® family includes trophon® EPR and trophon®2 which share the same core technology of 'sonically activated' hydrogen peroxide.

  1. Vickery, K., et al. (2014). "Evaluation of an automated high-level disinfection technology for ultrasound transducers." J Infect Public Health 7(2): 153-160.
  2. Becker, B., et al. (2017). "Virucidal efficacy of a sonicated hydrogen peroxide system (trophon(®) EPR) following European and German test methods." GMS Hygiene and Infection Control 12: Doc02.
  3. Ryndock, E., et al. (2016). "Susceptibility of HPV16 and 18 to high level disinfectants indicated for semi-critical ultrasound probes." J Med Virol 88(6): 1076-1080.
  4. Buescher, D. L., et al. (2016). "Disinfection of transvaginal ultrasound probes in a clinical setting: comparative performance of automated and manual reprocessing methods." Ultrasound Obstet Gynecol 47(5): 646-651.
  5. Ngu, A., et al. (2015). "Reducing Transmission Risk Through High-Level Disinfection of Transvaginal Ultrasound Transducer Handles." Infect Control Hosp Epidemiol 36(5): 1-4.
Next
Demonstrated Compliance